The Sequencing and Viral Evolution Core (Core B) will support deep sequencing and bioinformatic analysis of samples from the U19 consortium. Two types of samples will be analyzed. 1) The core will analyze sites of vector integration longitudinally following transduction with lentiviral vectors, with the goals of tracking the behavior of cell populations and scanning for adverse events. So far there have been no examples of transformation associated with integration of a lentiviral vector in T-cells, so we do not expect to detect any adverse events. The integration site tracking will focus primarily on reporting on the number of clones that give rise to transduced cells, and their longitudinal behavior. 2) The core will track HIV evolution in the presence of selective pressures from the C34-CXCR4 and CD4-CAR/CD8-CAR interventions by deep sequencing of HIV env in longitudinal samples. This study will be coupled with targeted analysis of escape mutations, providing specific targets to analyze. Any candidate escape mutations detected will be provided to the projects for follow up. Specific interactions with the four projects include the following. Core B will 1) characterize lentiviral integration sites as part of the safety monitoring of the Phase I clinical trial (Project 1); 2) work with Projects 1 and 2 to study resistance to X4-C34 (deep sequencing of virus), first in the humanized mouse model and then in patients; 3) work with Projects 2 and 3 to study HIV-1 resistance to CD4-CAR based therapy in the presence and absence of C34-CXCR4 modification; and 4) work with Project 4 to study persistence of gene-modified cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI117950-01
Application #
8899246
Study Section
Special Emphasis Panel (ZAI1-BP-A (J3))
Project Start
Project End
Budget Start
2015-04-10
Budget End
2016-03-31
Support Year
1
Fiscal Year
2015
Total Cost
$172,193
Indirect Cost
$62,193
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Fraietta, Joseph A; Nobles, Christopher L; Sammons, Morgan A et al. (2018) Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558:307-312
Medvec, Andrew R; Ecker, Christopher; Kong, Hong et al. (2018) Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium. Mol Ther Methods Clin Dev 8:65-74
Clarke, Erik L; Connell, A Jesse; Six, Emmanuelle et al. (2018) T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency. Genome Med 10:70
Stelekati, Erietta; Chen, Zeyu; Manne, Sasikanth et al. (2018) Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155. Cell Rep 23:2142-2156
Ecker, Christopher; Riley, James L (2018) Translating In Vitro T Cell Metabolic Findings to In Vivo Tumor Models of Nutrient Competition. Cell Metab 28:190-195
Ecker, Christopher; Guo, Lili; Voicu, Stefana et al. (2018) Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments. Cell Rep 23:741-755
Maldini, Colby R; Ellis, Gavin I; Riley, James L (2018) CAR T cells for infection, autoimmunity and allotransplantation. Nat Rev Immunol 18:605-616
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Veenhuis, Rebecca T; Kwaa, Abena K; Garliss, Caroline C et al. (2018) Long-term remission despite clonal expansion of replication-competent HIV-1 isolates. JCI Insight 3:
Chen, Gang; Huang, Alexander C; Zhang, Wei et al. (2018) Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560:382-386

Showing the most recent 10 out of 27 publications